Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Qlt Inc

Home Clinical Trial Sponsors and OrganizationsQlt Inc

Qlt Inc

2579 Midpoint Dr, Fort Collins, Colorado, United States

Also known as:

qlt ophthalmics, inc.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

24

5 active

Approvals

2

Total approvals

Agencies

1

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

9

37.5%

Phase 2

6

25.0%

Phase 3

4

16.7%

Trial Status Distribution

Active, not recruiting

5

20.8%

Completed

14

58.3%

Terminated

5

20.8%

Clinical Trials

Trials sponsored by this organization (24)

A study in subjects with rare inherited eye conditions caused by gene mutations to see if treatment with QLT091001 is safe and works to improve subjects' vision.

Active, not recruiting

Sep 201648 participants

A study in subjects with rare inherited eye conditions caused by gene mutations to see if treatment with QLT091001 is safe and works to improve subjects' vision.

Active, not recruiting

Sep 201648 participants

Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT

Dec 201559 participants

Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation

Nov 201343 participants

A study in patients with rare inherited eye conditions (Leber Congenital Amaurosis or Retinitis Pigmentosa), to see if repeated treatment with the study drug, QLT091001, is safe and works to improve patients' visio

Active, not recruiting

May 201231 participants

A study in patients with rare inherited eye conditions (Leber Congenital Amaurosis or Retinitis Pigmentosa), to see if repeated treatment with the study drug, QLT091001, is safe and works to improve patients' visio

Active, not recruiting

May 201231 participants

A study in patients with rare inherited eye conditions (Leber Congenital Amaurosis or Retinitis Pigmentosa), to see if repeated treatment with the study drug, QLT091001, is safe and works to improve patients' visio

Active, not recruiting

May 201231 participants

Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)

Feb 20125 participants

Page 1 of 3

Approvals

Approvals by Agency

FDA

Food and Drug Administration

2

Approvals

Recent Approvals

News

No news articles found

On this page

Overview
Clinical Trials24
Approvals2
News

Back to Organizations